MedTrace Logo

A Cohort Study of Operationally Tolerant Allograft Recipients

NCT02743793 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2021-09-21

Study results available
· View outcomes & findings →

Summary

Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ. Some organ transplant recipients can stop taking anti-rejection medicines without rejecting their transplanted organ (this is called 'tolerance'). The purpose of this study will collect samples and data from 'tolerant' liver or kidney transplant recipients in order to find out:

The purpose of this study is to collect samples and data in order to find out:

* How long liver or kidney transplant recipients can remain tolerant;
* What happens in the tolerant recipient's body over time; and
* If there are patterns in the body that are linked to tolerance.

Conditions

  • Kidney Transplant
  • Liver Transplant

Interventions

PROCEDURE

Blood Draw

Sponsors & Collaborators

  • Immune Tolerance Network (ITN)

    collaborator NETWORK

  • PPD Development, LP

    collaborator INDUSTRY

  • Rho Federal Systems Division, Inc.

    collaborator INDUSTRY

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Sindhu Chandran, M.D. · Immune Tolerance Network (ITN)

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2020-03-24
Completion
2020-03-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02743793 on ClinicalTrials.gov